Community Health Impact Coalition members & colleagues from across the world are sharing COVID-19 explainers, internal policies, clinical protocols, & more live
This is a guide for healthcare workers involved in patient care activities in a healthcare setting. It aims to show the type of personal protective equipment or PPE needed to correctly protect oneself. Based on the current available evidence, the WHO recommended PPE for the care of COVID patients ar...e CONTACT and DROPLET precautions, with the exception of aerosol producing procedures, which require CONTACT and AIRBORNE (hence, a respirator mask such as N95, FFP2, FFP3). Keeping in mind, PPE is part of a larger infection prevention and control bundle of measures and should be implemented as part of a multimodal strategy of management of COVID-19 patients. Only clinical staff who are trained and competent in the use of PPE should be allowed to enter the patient’s room.
This course is also available in the following languages:
العربية -македонски - 中文 - Shqip - français - ภาษาไทย - Português - Español - Nederlands - Tetun
more
People in prisons and other places of detention live in a closed environment and in close proximity with one another – conditions that facilitate transmission of diseases. They also have a greater underlying burden of disease and worse health conditions than the general population, and frequently ...face greater exposure to risks such as smoking, poor hygiene and weak immune defence due to stress, poor nutrition or existing diseases. All these factors make people living in prison more susceptible to infections.
more
User Guide.
This Laboratory Assessment Tool (LAT) is specifically designed to assess capacities of existing laboratories which have implemented or aim to implement SARS-CoV-2 testing. It addresses both core capacities of a laboratory and specificities related to SARS-CoV-2 testing. It is a focused... and shorter version from the existing complete laboratory assessment tool that can be found at https://www.who.int/ihr/publications/laboratory_tool/en/
The target audience is any stakeholder performing laboratory assessments such as national health authorities, multilateral agencies, Non-Governmental Organizations (NGOs) and laboratory managers. Assessors can use the tool, and customized if needed, to meet local requirements or assessment context. This tool is an Excel file, which enables automatic calculations of module indicators.
https://www.who.int/publications/i/item/laboratory-assessment-tool-for-laboratories-implementing-covid-19-virus-testing
more
This document is to support local authorities, leaders and policy-makers in cities and other urban settlements in identifying effective approaches and implementing recommended actions that enhance the prevention, preparedness and readiness for COVID-19 in urban settings, to ensure a robust response ...and eventual recovery. It covers factors unique to cities and urban settings, considerations in urban preparedness, key areas of focus and preparing for future emergencies.
more
Efficient triage of patients with COVID-19 at all health facility levels (primary, secondary and tertiary) will help the national response planning and case management system cope with patient influx, direct necessary medical resources to efficiently support the critically ill and protect the safety... of health-care workers. The objective of this algorithm is to give overall guidance for the triage and referral of symptomatic COVID-19 patients. Intended for use by ministries of health, hospital administrators and health workers involved in response planning for COVID-19 and/or patient triage, management and referral, this algorithm provides a general framework to be adapted to local health systems in countries.
more
The COVID-19 Supply Portal is a purpose-built tool to facilitate national authorities and all implementing partners supporting COVID-19 National Action Plans to request critical supplies.
The ongoing COVID-19 pandemic presents an exceptional and unprecedented challenge for competent authoritiesa with responsibilities for national food safety control systemsb to continue conducting routine functions and activities in accordance with national regulations... and international recommendations. In many countries, competent authority staff are largely working from home, teleworking being the normal practice, and all face-to-face meetings cancelled or rescheduled as teleconferences. It is challenging to maintain, without interruption, routine activities such as the inspection of food business operations, certifying exports, control of imported foods, monitoring and surveillance of the safety of the food supply chain, sampling and analysis of food, managing food incidents, providing advice on food safety and food regulations for the food industry, and communicating on food safety issues with the public.
more
Updated 20 Nov. 2020
Countries can use this checklist of hospital governance, structures, plans and protocols to rapidly determine the current capacities of hospitals to respond to the COVID-19 pandemic and to identify gaps and major areas that require investment and action for the development of h...ospital readiness improvement plans. The tool can be used periodically to monitor hospital emergency operational readiness capacity development
more
This guideline document lays out the indicators for monitoring the 2016 Political Declaration on ending AIDS. The Global AIDS Monitoring (GAM) process has been often referenced as a benchmark for successful international accountability mechanisms.
10 July 2020
Guidance for authorities and event organizers planning mass gatherings during the current COVID-19 pandemic
The content of this Risk Assessment tool has been updated to reflect new WHO guidance and new evidence on both COVID-19 and mass gatherings, as well as feedback from end-users.
...
Additional improvements have been made to the way the information is organized and presented: the Decision Tree is now built into the tool and a new tab dedicated to Risk Communication has been added. The expanded tool now includes six tabs: 1. Instructions; 2. Decision Tree; 3. Risk Evaluation; 4. Risk Mitigation; 5. Decision Matrix; 6. Risk Communication.
more
This document provides a decision-making framework for implementation of mass treatment interventions, active case-finding campaigns and population-based surveys for neglected tropical diseases in the context of the COVID-19 pandemic. A two-step approach is proposed: a risk–benefit assessment, to ...decide if the planned activity should proceed; and an examination of a list of precautionary measures that should be applied with the aim of decreasing the risk of transmission of COVID-19 associated with the activity, and strengthening the capacity of the health system to manage any residual risk. This guidance note is intended to health authorities, NTD programme managers and their supporting partners.
more
For COVID-19, as for many infectious diseases, the true level of transmission is frequently underestimated because a substantial proportion of people with the infection are undetected either because they are asymptomatic or have only mild symptoms and thus typically fail to present at healthcare fac...ilities. There may also be neglected or under-served segments of the population who are less likely to access healthcare or testing. Under-detection of cases may be exacerbated during an epidemic, when testing capacity may be limited and restricted to people with severe cases and priority risk groups (such as frontline healthcare workers, elderly people and people with comorbidities). Cases may also be misdiagnosed and attributed to other diseases with similar clinical presentation, such as influenza.
Differences in mortality between groups of people and countries are important proxy indicators of relative risk of death that guide policy decisions regarding scarce medical resource allocation during the ongoing COVID-19 pandemic. This document is intended to help countries estimate CFR and, if possible, IFR, as appropriately and accurately as possible, while accounting for possible biases in their estimation
more
In 2016, the risk of premature mortality1 from noncommunicable diseases (NCDs) in Ethiopia was 18.3%. The economic costs of NCDs are significant and are due principally to their impact on the non-health sector (reduced workforce and productivity). In this study, it is estimated that NCDs cost Ethiop...ia at least 31.3 billion birr (US$ 1.1 billion) per year, equivalent to 1.8% of the gross domestic product (GDP). Less than 15% of the costs are for health care.
more
The COVID-19 pandemic affects older people disproportionately, especially those living in long-term care facilities (LTCF) with significant impact on mortality and morbidity. Concerted action is needed to mitigate the impact of COVID-19 by enhancing infection prevention and control (IPC) measures wi...thin LTCF. The COVID-19 IPC course for LTCF consists of 4 training modules to be used in conjunction with the LTCF communication toolkit and preparedness checklist. This package is tailored for LTCF and based on WHO's in-depth technical guidance on IPC.
This course is also available in the following languages: Bahasa Indonesia - Nederlans
more
The Access to COVID-19 Tools (ACT) Accelerator’s Country Readiness and Delivery workstream has released guidance on developing a national deployment and vaccination plan (NDVP) for COVID-19 vaccines. This course is intended to help national and sub-national focal points in countries develop the ND...VP and prepare for COVID-19 vaccine introduction.
Available in English and Macedonian
more
17 February 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
This e-course will guide you through the essentials of latest existing WHO guidelines and policy recommendations on drug-resistant TB. You will also learn more about the rationale behind the WHO recommendations for the management of DR-TB, implementation considerations for different regimens for eli...gible patient groups, adjunctive treatment, the active TB drug safety monitoring and management framework, and the analysis and interpretation of performance indicators.
The main focus of the e-course is programmatic; clinical aspects are only discussed when relevant to specific topics.
more